{
    "clinical_study": {
        "@rank": "158158", 
        "arm_group": [
            {
                "arm_group_label": "Prophylaxis group", 
                "description": "Prophylaxis with FEIBA is defined in this study as the regular infusion of FEIBA for the prevention of bleeding at a dose of \u226550 UF/kg on at least three non-consecutive days a week. Patients must have been on this modality for at least 6 months prior to the study visit"
            }, 
            {
                "arm_group_label": "On demand group", 
                "description": "On-demand Treatment is defined as the administration of FEIBA only to control bleeding. Patients must have been on this modality for at least 6 months prior to the study visit."
            }
        ], 
        "brief_summary": {
            "textblock": "This study aims to evaluate the immunomodulatory effect of FEIBA\u00ae in patients with severe\n      haemophilia A and inhibitors."
        }, 
        "brief_title": "Case-control Pilot Study of the Immune Modulating Effect of FEIBA on Patients With Haemophilia A and Inhibitors", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Severe Haemophilia A With Inhibitors", 
        "condition_browse": {
            "mesh_term": "Hemophilia A"
        }, 
        "detailed_description": {
            "textblock": "This is an observational, multicentric, case-control and one-single-visit study of patients\n      with severe haemophilia A and inhibitors against FVIII in therapy with FEIBA\u00ae.\n\n      Two subject groups will be included: Group 1 (cases) will be composed of patients with\n      severe haemophilia A and inhibitors in prophylaxis with FEIBA\u00ae; Group 2 (controls) will be\n      composed of patients with severe haemophilia A and inhibitors on-demand treatment with\n      FEIBA\u00ae."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. The subject has signed and dated the Informed Consent form for participation in this\n             study.\n\n          2. Age \u2265 18 years old.\n\n          3. Patient with severe haemophilia A (FVIII <1%) and high-responding inhibitor (titre >5\n             UB) at some point in their life, currently on therapy with FEIBA\u00ae to control\n             bleeding.\n\n          4. Group 1: Patients in prophylaxis with FEIBA\u00ae: The patient has been on prophylaxis\n             regimen with FEIBA\u00ae for at least 6 months prior to the study visit. Group 2: Patients\n             on-demand regimen with FEIBA\u00ae: The patient has been under on-demand treatment with\n             FEIBA\u00ae for at 6 months prior to the study visit.\n\n        Exclusion Criteria:\n\n          1. The presence of any inflammatory condition at the time of the study visit or the\n             previous 30 days that, according to the medical criterion, would affect the study\n             objectives.\n\n          2. The patient is under immune tolerance treatment  or has been at any time during the\n             30 days prior to the study visit.\n\n          3. The administration of any anti-inflammatory or immunosuppressive drug 15 days before\n             the study visit.\n\n          4. Levels of CD4 <200/l regardless of the HIV status.\n\n          5. Altered hepatic or renal function defined by the presence of abnormal levels of\n             alanine aminotransferase (ALAT) or serum creatinine, respectively.\n\n          6. Administration of any haemostatic treatment to control bleeding within the 5 days\n             prior to the study visit."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with severe haemophilia A and inhibitors treated with FEIBA\u00ae (on demand or\n        prophylaxis) for the control of bleedings."
            }
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02018393", 
            "org_study_id": "PI-1405"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "FEIBA\u00ae", 
        "lastchanged_date": "December 20, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Madrid", 
                    "country": "Spain", 
                    "zip": "28046"
                }, 
                "name": "University Hospital La Paz"
            }, 
            "status": "Active, not recruiting"
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_groups": "2", 
        "official_title": "Case-control Pilot Study of the Immune Modulating Effect of FEIBA on Patients", 
        "overall_contact": {
            "email": "ihosvanyf@yahoo.es", 
            "last_name": "Ihosvany Fernandez-Bello, Pharmacist", 
            "phone": "+34669089737"
        }, 
        "overall_official": {
            "affiliation": "Hospital Universitario La Paz", 
            "last_name": "Victor Jimenez-Yuste, Medical doctor, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Spain: Spanish Agency of Medicines and Medical Devices"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Measurement of plasma levels of anti-FVIII antibodies (neutralising and non-neutralising)", 
            "safety_issue": "No", 
            "time_frame": "At inclusion"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02018393"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Hospital Universitario La Paz", 
            "investigator_full_name": "Victor Jimenez-Yuste", 
            "investigator_title": "Medical Degree PhD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Measurement of the serum levels of inflammatory cytokines", 
            "safety_issue": "No", 
            "time_frame": "At inclusion"
        }, 
        "source": "Hospital Universitario La Paz", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hospital Universitario La Paz", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Observational Model: Case Control, Time Perspective: Cross-Sectional", 
        "study_type": "Observational", 
        "verification_date": "December 2013"
    }
}